An italian biopharmaceutical company
The company is focused on the discovery, development and commercialization of monoclonal antibodies
Partnering
MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.
However, we are interested in forging partnership alliances at all development stages should such arrangements facilitate the rapid development of the product.
Tag Cloud
European Venture contest
biopharmaceutical company
Istituto Superiore di Sanita
Monoclonal antibodies
Cancer targeted therapy
mouse monoclonal antibody
Cancer biodiagnostics
development
European cancer drug company
Therapeutic antibodies
cancer monoclonal companies
antibodies monoclonal
mediapharma l31 antibody
Cancer drug companies
pharmaceutical company
monoclonal antibodies cancer
research antibodies
Research & Development
SP-2 0.1 mg Affinity purified
Scientific Advisory Board
anticorpi monoclonali
Cancer biological therapy
products based on monoclonal antibodies
Business development
mediapharma
Subscribe to Rss Feed
ShareMediaPharma s.r.l. P.IVA.: IT 02282760699 | Rea di Chieti: 166532
The information provided on www.mediapharma.it is designed to complement, not replace, the relationship between a patient and his/her own physician.
